|
Title
|
|
|
|
C-terminal neurogranin is increased in CSF but unchanged in plasma in Alzheimer's disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background: Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimers disease (AD) diagnosis. Post-synaptic protein neurogranin may be a promising CSF biomarker but has not yet been evaluated as plasma biomarker. Methods: Using an in-house designed prototype ELISA targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n=29) versus patients experiencing MCI, or dementia, due to AD (in total n=59). Results: CSF neurogranin was increased in AD and positively correlated with CSF tau while there was a negative relationship between CSF neurogranin (and tau) and CSF Aβ1-42/Aβ1-40. No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter. Conclusions: This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immuno-assays can be used, as demonstrated by the described ELISA. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Alzheimer's & dementia / Alzheimer’s Association [Chicago, Ill.] - Orlando, Fla, 2005, currens
| |
|
Publication
|
|
|
|
Orlando, Fla
:
Elsevier
,
2015
| |
|
ISSN
|
|
|
|
1552-5260
[print]
1552-5279
[online]
| |
|
DOI
|
|
|
|
10.1016/J.JALZ.2015.05.012
| |
|
Volume/pages
|
|
|
|
11
:12
(2015)
, p. 1461-1469
| |
|
ISI
|
|
|
|
000366721600007
| |
|
Pubmed ID
|
|
|
|
26092348
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|